Airway Epithelium Gene Expression: AEGIS IDE

NCT ID: NCT00746759

Last Updated: 2015-06-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1331 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-02-28

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Allegro Diagnostics is funding this multi-center study to validate and extend a new diagnostic tool measuring global gene expression in airway epithelial cells obtained at routine bronchoscopy in suspect lung cancer patients. The test, which is highly sensitive and specific for lung cancer, measures the levels of expression of genes in cells brushed from the large bronchi during diagnostic bronchoscopy. Similar brushings of epithelial cells from the nose will be analyzed to determine if gene expression in these cells can be used as a screening tool in subjects who may have now or be at risk for developing lung cancer in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care

Biomarker (not used as an intervention)

Intervention Type DEVICE

This study is an observational study. There is no intervention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biomarker (not used as an intervention)

This study is an observational study. There is no intervention.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BronchoGen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients being evaluated for the diagnosis of possible lung cancer or "rule out lung cancer" and undergoing clinically indicated bronchoscopy
* All patients are required to be at least 21 years of age and be able to understand and sign the informed consent form
* Patient must be a current or former cigarette smoker

Exclusion Criteria

* A pulmonary physician does not recommend that bronchoscopy be performed
* Inability to understand the written consent form and comply with requirements of the study
* History of prior primary lung cancer
* Immediately prior to bronchoscopy, the patient has been on a mechanical ventilator for \>24 consecutive hours.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pennsylvania

OTHER

Sponsor Role collaborator

Columbia University

OTHER

Sponsor Role collaborator

Temple University

OTHER

Sponsor Role collaborator

Indiana University

OTHER

Sponsor Role collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role collaborator

University of Missouri-Columbia

OTHER

Sponsor Role collaborator

Louisiana State University Health Sciences Center in New Orleans

OTHER

Sponsor Role collaborator

University of Wisconsin, Madison

OTHER

Sponsor Role collaborator

Medical University of South Carolina

OTHER

Sponsor Role collaborator

National Jewish Health

OTHER

Sponsor Role collaborator

Overlake Hospital Bellevue WA

UNKNOWN

Sponsor Role collaborator

Pulmonary and Allergy Associates of New Jersey

UNKNOWN

Sponsor Role collaborator

Pulmonary Associates of Arizona

UNKNOWN

Sponsor Role collaborator

William Jennings Bryan Dorn VA Medical Center

FED

Sponsor Role collaborator

Virginia Commonwealth University

OTHER

Sponsor Role collaborator

Jamaica Hospital Medical Center

OTHER

Sponsor Role collaborator

North Florida/South Georgia Veterans Health System

OTHER

Sponsor Role collaborator

Steward St. Elizabeth's Medical Center of Boston, Inc.

OTHER

Sponsor Role collaborator

University of California, Davis

OTHER

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role collaborator

The Cleveland Clinic

OTHER

Sponsor Role collaborator

Allegro Diagnostics, Corp.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Duncan Whitney, PhD

Role: STUDY_DIRECTOR

Allegro Diagnostics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama

Birmingham, Alabama, United States

Site Status

Pulmonary Associates of Arizona

Phoenix, Arizona, United States

Site Status

University of California- Davis

Sacramento, California, United States

Site Status

National Jewish Health

Denver, Colorado, United States

Site Status

Yale Univeristy

New Haven, Connecticut, United States

Site Status

North Florida/South Georgia VA

Gainesville, Florida, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

LSU

New Orleans, Louisiana, United States

Site Status

St. Elizabeth's Medical Center

Boston, Massachusetts, United States

Site Status

University of Missouri

Columbia, Missouri, United States

Site Status

Pulmonary and Allergy Associates of New Jersey

Summit, New Jersey, United States

Site Status

Jamaica Hospital Medical Center

Jamaica, New York, United States

Site Status

Columbia University

New York, New York, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Temple University

Philadelphia, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

Dorn VA

Columbia, South Carolina, United States

Site Status

Virginia Commonwealth University

Richmond, Virginia, United States

Site Status

Overlake Hospital

Bellevue, Washington, United States

Site Status

University of Wisconsin

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Vachani A, Whitney DH, Parsons EC, Lenburg M, Ferguson JS, Silvestri GA, Spira A. Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer. Chest. 2016 Jul;150(1):210-8. doi: 10.1016/j.chest.2016.02.636. Epub 2016 Feb 16.

Reference Type DERIVED
PMID: 26896702 (View on PubMed)

Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, Parsons E, Mitra N, Brody J, Lenburg ME, Spira A; AEGIS Study Team. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med. 2015 Jul 16;373(3):243-51. doi: 10.1056/NEJMoa1504601. Epub 2015 May 17.

Reference Type DERIVED
PMID: 25981554 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ADx-0001: IDE G090194

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nashville Early Diagnosis Lung Cancer Project
NCT01475500 ACTIVE_NOT_RECRUITING
Early Detection of Lung Cancer
NCT03181256 ACTIVE_NOT_RECRUITING